Out-licensing

7-substituted Camptothecin and Camptothecin Analogues

Introduction/Background

Camptothecin (CPT) is a naturally occurring cytotoxic alkaloid which is known to inhibit the enzyme topoisomerase I and is a potent anti-tumour agent.

Aims/Hypothesis

A need continues to exist, however, for a method of preparing 7-substituted camptothecin compounds.

Research

Methods of forming camptothecin compounds which are effective anti-tumour compounds are disclosed. These compounds inhibit the enzyme topoisomerase I and may alkylate DNA of the associated topoisomerase I-DNA cleavable complex.

Conclusion

Major synthetic efforts have been directed to derivatizing the B-ring at C7 to improve cytotoxic and in vivo activity.


Relevance/Opportunity

Please enquire regarding licensing or codevelopment partnerships.

Preclinical

Patent No.: 7067666